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Background. Human immunodeficiency virus (HIV)–infected patients coinfected with hepatitis B (HBV) and C (HCV) viruses
are at increased risk of end-stage liver disease (ESLD). Whether modern antiretroviral therapy has reduced ESLD risk is unknown.
Methods. Twelve clinical cohorts in the United States and Canada participating in the North American AIDS Cohort Collab-
oration on Research and Design validated ESLD events from 1996 to 2010. ESLD incidence rates and rate ratios according to hepatitis
status adjusted for age, sex, race, cohort, time-updated CD4 cell count and HIV RNAwere estimated in calendar periods correspond-
ing to major changes in antiretroviral therapy: early (1996–2000), middle (2001–2005), and modern (2006–2010) eras.
Results. Among 34 119 HIV-infected adults followed for 129 818 person-years, 380 incident ESLD outcomes occurred. ESLD
incidence (per 1000 person-years) was highest in triply infected (11.57) followed by HBV- (8.72) and HCV- (6.10) coinfected vs 1.27
in HIV-monoinfected patients. Adjusted incidence rate ratios (95% confidence intervals) comparing the modern to the early anti-
retroviral era were 0.95 (.61–1.47) for HCV, 0.95 (.40–2.26) for HBV, and 1.52 (.46–5.02) for triply infected patients. Use of anti-
retrovirals dually activity against HBV increased over time. However, in the modern era, 35% of HBV-coinfected patients were not
receiving tenofovir. There was little use of HCV therapy.
Conclusions. Despite increasing use of antiretrovirals, no clear reduction in ESLD risk was observed over 15 years. Treatment with
direct-acting antivirals for HCV and wider use of tenofovir-based regimens for HBV should be prioritized for coinfected patients.
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It has been estimated that 10 million (30%) human immunode-
ficiency virus (HIV)–infected persons worldwide are coinfected
with chronic hepatitis C virus (HCV) [1] and 3 to 5 million
(5%–15%) with chronic hepatitis B virus (HBV) [2, 3]. HIV ac-
celerates liver disease caused by both HBV and HCV and may
itself cause liver injury [4]. HIV replication and associated im-
mune dysfunction are correlated with liver disease progression
in the setting of coinfection [5], whereas sustained HIV control
may reduce liver fibrosis and hepatic decompensation [6, 7].
HIV therapy has evolved so that treatments are now safer,
more effective, and widely accessible in the United States and
Canada, resulting in most HIV-infected adults in care achieving
prolonged HIV suppression, immune reconstitution, and re-
duced mortality from AIDS [8]. HIV-infected people now sur-
vive long enough to develop complications of chronic viral
hepatitis, particularly end-stage liver disease (ESLD) and hepa-
tocellular carcinoma, which have become leading causes of
morbidity and mortality [9, 10].
The extent to which HIV treatment and viral suppression
have reduced the risk of ESLD is not known. HIV therapy itself
can have dual activity against HBV. Lamivudine (3TC) sup-
presses HBV DNA, although resistance develops rapidly and
more commonly in HIV-infected patients [11, 12]. However, te-
nofovir (TDF) with/or without 3TC or emtricitabine (FTC) as
part of an HIV treatment regimen can be used to achieve pro-
longed suppression of HBV DNA and potentially reduce liver
disease outcomes [13].HCV-coinfected patients on combination
antiretroviral therapy (ART) appear to remain at increased risk
for hepatic decompensation compared with HCV-monoinfected
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patients [7]. Recent advances in HCV therapies have resulted in
greater cure rates and have the potential to dramatically reduce
the risk of ESLD, although, until recently, these therapies have
not been widely used. Understanding how ESLD risk has evolved
since the introduction of effective ART is necessary to gauge the
potential impact of new HCV therapies.
Our objective in this study was to estimate temporal trends in
ESLD among HIV-infected persons with and without HBV and
HCV coinfection by calendar periods that correspond to major
changes in ART availability, safety, and clinical practice prior to
the widespread use of direct-acting HCV therapies.
METHODS
Study Population
The North American AIDS Cohort Collaboration on Research
and Design (NA-ACCORD) is a consortium of clinical and in-
terval HIV cohorts from Canada and the United States and has
been described elsewhere [14]. Briefly, NA-ACCORD consists
of 25 cohorts that collect data on more than 150 000 HIV-
infected persons engaged in clinical care at more than 200 clin-
ical sites [15]. At scheduled intervals, cohorts securely transfer
demographic, medication, laboratory, diagnostic, and vital sta-
tus information to the central Data Management Core (Univer-
sity of Washington), where data undergo quality control and are
harmonized for analyses by the Epidemiology/Biostatistics Core
(Johns Hopkins University). The human subject research activ-
ities of the NA-ACCORD and each participating cohort have
been approved by their respective local institutional review
boards and the Johns Hopkins School of Medicine.
All HIV-infected adults aged ≥18 years seeking care in the 12
(10 in United States and 2 in Canada) NA-ACCORD clinical
cohorts that participated in a substudy validating ESLD diag-
noses from 1 January 1996 to 31 December 2010 were eligible.
We excluded prevalent ESLD cases, defined as participants who
had validated ESLD prior to or within 3 months of cohort entry.
Outcome: Validated End-Stage Liver Disease
Twelve clinical cohorts used medical record review to validate
cases of ESLD as previously described [16]. Criteria for ESLD
ascertainment were determined centrally using a screening al-
gorithm developed by the NA-ACCORD, which selected pa-
tients with laboratory and/or clinical diagnoses or procedures
suggestive of ESLD (ie, paracentesis, liver transplant) to under-
go validation for ESLD events [16]. Laboratory criteria included
2 validated noninvasive laboratory-based measures of hepatic fi-
brosis: the aspartate aminotransferase/platelet ratio index
(APRI) [17] and fibrosis-4 (FIB-4) [18] using predefined cutoffs
indicative of significant fibrosis (eg, at least 2 APRI scores >1.5
or 2 FIB-4 scores >3.25, more than 6 months apart) and at least
1 of the following other laboratory abnormalities that indicate
impaired hepatic function: total bilirubin ≥5 mg/dL, albumin
<20 g/L, or an international normalized ratio >1.7. Diagnostic
criteria included any single clinician-documented diagnostic
or procedure code consistent with ESLD [16]. Each potential
case identified then underwent validation for ESLD by review
of all available medical records by (or under the supervision
of ) a physician at each cohort. A centralized web-based appli-
cation was used to standardize ESLD data collection and con-
firm evidence of 1 of the following diagnoses: ascites,
spontaneous bacterial peritonitis, variceal hemorrhage, hepatic
encephalopathy, or hepatocellular carcinoma. The earliest con-
firmed diagnosis date of ESLD was used.
Exposures: Hepatitis B and C Infection
HBV infection was defined by the presence of a positive hepa-
titis B surface antigen, hepatitis B e antigen, or a detectable hep-
atitis B DNA result measured at any time while under
observation. HCV infection was defined as a positive HCV an-
tibody or detectable HCV RNA or genotype result measured at
any time while under observation. Both HBV and HCV infec-
tions were measured as time-fixed variables due to the likeli-
hood that the infection occurred around the time of HIV
infection (which would be prior to entry into the NA-
ACCORD), regardless of when documentation of HBV or
HCV status occurred. Triply infected patients were HIV-,
HBV-, and HCV-infected.
Covariates of Interest
Race (black, white, or other/unknown) and history of injection
drug use (IDU) were self-reported at enrollment into the local
cohort. ART was defined as a combination of 3 antiretroviral
agents from at least 2 classes or a triple nucleoside/nucleotide
reverse transcriptase inhibitor regimen containing abacavir or
TDF. ART exposure was time updated in each calendar period
(below). Exposure to ART and to medications with specific
HBV activity—3TC, FTC, and TDF—was assessed as having
any use for a period of at least 1 month in a given treatment era.
We defined 3 periods of calendar time of interest: the early
(1996–2000), middle (2001–2005), and modern (2006–2010)
ART eras, which roughly correspond to when major changes
in ART regimens (eg, safety, tolerability, and effectiveness)
and clinical practice took place. For example, 2001 guidelines
changed to recommend treating all patients with CD4 < 350
cells/mm3 [19] and, in 2004, HCV and HBV-coinfected patients
were first recognized as constituting special populations [20].
TDF received US Food and Drug Administration approval in
2001 [21], and TDF combined with lamivudine (3TC) or/emtri-
citabine (FTC) was first recommended as the preferred nucleo-
side backbone for treating HIV in patients coinfected with HBV
in 2006 [22].
Due to changes in the sensitivity of HIV RNA assays during
the study period, HIV suppression was defined as <500 copies/
mL, with each individual’s minimum HIV RNAmeasure select-
ed in each of the time periods.
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Heavy alcohol use was defined as ever having been reported
while in the NA-ACCORD: ≥3 drinks on any day or ≥7 drinks
per week for females and ≥4 drinks on any day or ≥14 drinks
per week for males. Individuals from cohorts that did not pro-
vide alcohol information were classified as not assessed (63%).
Statistical Analyses
Person-time and ESLD events accrued from baseline to study
exit. Baseline was defined as enrollment into the NA-ACCORD,
the start of the ESLD observation window for the patient’s co-
hort (defined as the period of time during which ESLD events
are believed to be 100% ascertained for each cohort), or 1 Jan-
uary 1996, whichever occurred last. Study exit was defined as
ESLD diagnosis date, death date, 1 year after the date of the pa-
tient’s last CD4 or HIV RNA (as a measure of loss to follow-up),
the end of the ESLD observation window for the patient’s co-
hort, or 31 December 2010, whichever occurred first.
Poisson regression models were used to estimate adjusted
ESLD incidence rates (IRs) per 1000 person-years and incidence
rate ratios (IRRs) with associated 95% confidence intervals
(CIs) in each of the ART eras according to HBV and HCV sta-
tus. IRRs were adjusted for age group (<40, 40–49, 50–59, 60–
69, and ≥70 years), sex, race, cohort, and time-updated CD4 cell
count and HIV RNA suppression (HIV RNA <500 copies/mL),
a surrogate marker for the effectiveness of ART, in each era.
The competing risk of death (eg, from AIDS) may have pre-
cluded more ESLD events in the early and middle ART eras vs
the modern ART era. We therefore conducted a sensitivity anal-
ysis to estimate the probability of ESLD at specific times (2.5, 5,
7.5, and 10 years after study entry) from the parametric cumu-
lative incidence functions of ESLD by HBV and HCV status and
by ART era after accounting for the competing risk of death [23]
to determine the effect of declining mortality among HIV-
infected adults during the study period (1996–2010). Deaths
were ascertained through clinical records, matching to provin-
cial registries, the US National Death Index, and the Social Se-
curity Death Index.
All analyses were performed using SAS version 9.4 (Carey,
North Carolina).
RESULTS
Study Population Characteristics
Of 41 405 HIV-infected patients followed in the 12 cohorts par-
ticipating in the ESLD validation, 34 119 (82%) met inclusion
criteria (see Supplementary Figure 1). Overall, 6347 (19%) pa-
tients had documented coinfection with HCV only, 1696 (5%)
with HBV only, and 533 (2%) were triply infected. Among the
6880 patients with HCV (with or without HBV), 92% had a
positive HCV antibody test, 63% had an HCV RNA test result
(of whom 91% were detectable), and 24% had an HCV geno-
type test; 37% were identified as HCV infected based solely
on an HCV antibody positive test. HBV DNA was available in
only 40% of those classified as HBV infected. Overall, 380 indi-
viduals developed a validated ESLD event during 129 818 per-
son-years of follow-up (IR = 2.9; 95% CI, 2.7, 3.2 per 1000
person-years). The median follow-up was 2.9 years (interquar-
tile range, 1.4, 5.6).
Baseline characteristics of patients are shown in Table 1,
stratified by ESLD status. Patients developing ESLD were
older, more likely to be male, white, have a history of IDU, be
infected with HCV and/or HBV, have baseline APRI score >1.5,
an FIB-4 score >3.25, CD4 cell count <200 cells/µL, and detect-
able HIV RNA. Overall, the proportion of patients with liver fi-
brosis by either measure did not vary by calendar period. In the
subset of patients with alcohol use data, patients developing
ESLD were also more likely to report heavy alcohol use.
End-Stage Liver Event Rates and Trends Over Time
The most frequent first ESLD diagnosis observed was ascites
(n = 274, 72%) followed by hepatic encephalopathy (n = 43,
11%), variceal hemorrhage (n = 37, 10%), hepatocellular carci-
noma (n = 24, 6%), and spontaneous bacterial peritonitis (n = 2,
1%). There were no apparent differences in the types of incident
ESLD events reported by either hepatitis status or ART era (see
Supplementary Table 1).
Overall, the highest rates of ESLD were observed in those
triply infected, followed by those coinfected with HBV, then
coinfected with HCV. Rates were substantially lower in HIV-
monoinfected patients in all ART eras (Figure 1 and Supple-
mentary Table 2). There was no evidence that ESLD event
rates changed appreciably over time nor among any category
of hepatitis infection, except possibly for a decrease in ESLD in-
cidence among those infected with HBV in the modern ART era
compared with earlier eras. A comparison of adjusted IRR for
ESLD between ART eras is shown in Table 2. There was no ev-
idence that ART era modified the effect of viral coinfection sta-
tus on ESLD incidence (test for interaction, P = .66).
Role of Antiviral Therapy
Increasing rates of HIV RNA suppression were observed over
calendar time, reaching 85% overall in the modern ART era
with no difference in suppression by hepatitis infection status
(Figure 2).
There was essentially no recorded use of HCV treatment dur-
ing the period of study (85 patients, 1%). The use of anti-HBV
active agents, however, increased substantially over time. TDF
use in particular increased dramatically starting in the middle
ART era (2001), reaching 71% in the modern ART era overall
(78% among those with HBV and 74% among those triply in-
fected; Figure 3). Of those with HBV infection, 73% were receiv-
ing ART in the modern ART era, of whom only 4% were not
receiving TDF, 3TC, or FTC. Taken together, 35% of HBV-
infected (alone or triply) individuals were not receiving TDF
in the modern ART era.
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Sensitivity Analysis
As expected, mortality rates were highest in the early ART era
and fell by approximately half by the modern ART era (see Sup-
plementary Figure 3). The cumulative incidence functions of
ESLD after accounting for the competing risk of death did
not differ over time within each HBV/HCV status group (see
Supplementary Figure 4A–D), suggesting minimal impact of
the decreasing competing risk of death on the incidence of
ESLD over time.
DISCUSSION
With more than 34 000 persons followed for 15 years, this study
is the largest and longest prospective evaluation of validated
ESLD outcomes conducted in an HIV-infected population.
ESLD events were common in all time periods studied and oc-
curred more frequently among those with viral hepatitis coin-
fection but were also observed in patients infected with only
HIV. Patients triply infected with HIV, HCV, and HBV were
at particularly high risk, having a 12-fold higher incidence
rate of ESLD compared with HIV-monoinfected patients,
even in the modern ART era. Even after accounting for compet-
ing risks of death, CD4, and HIV RNA suppression, we ob-
served no apparent improvement in ESLD rates in our HIV/
HCV-coinfected population.
Effective control of HIV replication has been shown to reduce
hepatic inflammation and fibrosis progression in the setting of
HIV coinfection in the short term [24]. There is some evidence
that liver-related morbidity and mortality have declined in more
recent calendar periods in some studies [25, 26] but not others
[27]. Reduced hepatic decompensation events in HIV/HCV-
coinfected men initiating ART compared with those never
receiving ART supports individual benefit of ART on ESLD risk
(adjusted hazard ratio, 0.72; 95% CI, .54–.94) [6]. This reduction,
however, could be partly counterbalanced by a reduction in the
competing risk of death from AIDS, creating a stalemate in
Figure 1. End-stage liver disease (ESLD) incidence rates and 95% confidence
intervals by viral hepatitis coinfection status and antiretroviral therapy (ART) era,
North American AIDS Cohort Collaboration on Research and Design, January
1996–December 2010. Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus.
Table 1. Baseline Characteristics Stratified by End-Stage Liver Disease,
NA-ACCORD, January 1996–December 2010
Characteristic
No ESLD
(N = 33 739)
ESLD
(N = 380)
n (%) n (%)
Age (y)
<40 16 615 (49) 145 (38)
40–49 11 853 (35) 144 (38)
50–59 4302 (13) 72 (19)
60–69 840 (2) 17 (4)
≥70 129 (0) 2 (1)
Male 26 559 (79) 325 (86)
Race
White 13 763 (41) 186 (49)
Black 11 955 (35) 122 (32)
Other/unknown 8021 (24) 72 (19)
History of injection drug use 4842 (14) 109 (29)
Hepatitis status
Hepatitis B infection only 1640 (5) 56 (15)
Hepatitis C infection only 6174 (18) 173 (46)
Hepatitis B and C infection 506 (1) 27 (7)
Hepatitis B uninfected and C uninfected 18 649 (55) 92 (24)
Not assessed 6770 (20) 32 (8)
Heavy alcohol use
Never 5616 (17) 45 (12)
Ever 6867 (20) 133 (35)
Not assessed 21 256 (63) 202 (53)
APRI score >1.5 1104 (3) 88 (23)
FIB-4 score >3.25 1104 (3) 91 (24)
CD4 < 200 cells/mm3 8646 (26) 146 (38)
HIV RNA ≥500 copies/mL 18 620 (55) 226 (59)
History of clinical AIDS diagnosis 7111 (21) 90 (24)
ART regimen
ART naïve 20 520 (61) 242 (64)
Protease inhibitor–based regimen 8309 (25) 106 (28)
Nonnucleoside reverse transcriptase
inhibitor–based regimen
4210 (12) 24 (6)
Other 700 (2) 8 (2)
Sex, race/ethnicity, and HIV transmission risk factor were collected at enrollment into the NA-
ACCORD and are time fixed. Age was measured as year of baseline − year of birth. Not
assessed was measured as lacking the necessary data to measure either hepatitis B
virus, hepatitis C virus, or both. Heavy alcohol use was defined as ever having reported
while under observation in the NA-ACCORD: ≥3 drinks on any day or 7 drinks per week
for females and ≥4 drinks on any day or 14 drinks per week males. Individuals from
cohorts that did not provide alcohol information were classified as not assessed.
Aspartate aminotransferase/platelet ratio index (APRI), a surrogate for liver fibrosis is
calculated as: [(AST level, in IU/L/AST upper limit of normal, in IU/L)/platelet count, in 109/
L)] * 100. APRI was estimated using AST and platelet measurements made at, or prior to,
baseline. FIB-4 is an alternate noninvasive score to estimate the amount of liver fibrosis,
calculated as: (age, in years) * (AST level, in IU/L)/(platelet count, in 109/L) * (square root
ALT, in IU/L). FIB-4 was estimated using AST, ALT, and platelet measurements made at,
or prior to, baseline. CD4 count and HIV RNA were measured as close to baseline as
possible, within a window period of 6 months before to 6 months after baseline. History
of clinical AIDS diagnoses was defined by International Classification of Diseases, Ninth
Revision, Clinical Modification codes for AIDS-defining illnesses, including pneumocystis
pneumonia, tuberculosis, mycobacterium, cytomegalovirus, HIV wasting, HIV dementia,
candidiasis, cryptococcosis, toxoplasmosis of the brain, coccidiomycosis, histoplasmosis,
isosporiasis, herpes zoster, herpes simplex, bacterial pneumonia, or Kaposi sarcoma;
history of clinical AIDS diagnosis was measured at, or prior to, baseline. ART was
measured as a combination of 3 antiretroviral agents from at least 2 classes or a triple
nucleoside/nucleotide reverse transcriptase inhibitor regimen containing abacavir or
tenofovir.
Abbreviations: ART, antiretroviral therapy; AST, aspartate aminotransferase; ESLD, end-
stage liver disease; FIB-4, fibrosis-4; HIV, human immunodeficiency virus; NA-ACCORD,
North American AIDS Cohort Collaboration on Research and Design.
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ESLD rates over time. Nonetheless, HIV/HCV-coinfected patients
continue to have higher rates of hepatic decompensation than
HCV-monoinfected patients [7]. Chronic toxicity of ART, persis-
tent immune dysfunction, and ongoing substance use may all con-
tribute to the residual increased risk of liver disease. Thus, while
ART is beneficial, it is clear that HIV control alone will be ineffec-
tive at reducing ESLD and that HCV therapy will be needed.
Although data on coinfection are still limited, HCV-monoin-
fected patients who are cured after HCV treatment have im-
proved survival, comparable with that of the general
population [28]. In the NA-ACCORD during the period
under study, there appeared to be minimal use of HCV
treatment. This is consistent with overall low treatment rates
in the United States and Canada (less than 10% in HCV overall
[29], 4% in coinfected veterans [6], and <1% in IDUs [30]) dur-
ing the interferon treatment era. The advent of safe and effec-
tive, all-oral, direct-acting antivirals (DAAs) has the potential to
dramatically affect the natural history of HCV in coinfection
[31]. However, concerted efforts are needed to address barriers
to DAA use, such as high treatment costs, complexities of ob-
taining reimbursement, and ongoing active substance use, in
order to broaden treatment access and ensure wide uptake in
this priority population [13]. It will be important to assess the
extent to which DAAs will impact the high rates of ESLD
Figure 2. Human immunodeficiency virus (HIV) RNA suppression by viral hepatitis coinfection status and antiretroviral therapy (ART) era, North American AIDS Cohort
Collaboration on Research and Design, January 1996–December 2010. Notes: HIV RNA suppression was defined as <500 copies/mL. Each patient’s minimum HIV RNA mea-
surement was selected in the time periods. The denominator for the proportions included all patients under observation during that time period, based on baseline and study
exit. Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus.
Table 2. Adjusted Incidence Rate Ratios and 95% Confidence Intervals of End-Stage Liver Disease in the Modern (2006–2010) and Middle (2001–2005) vs
Early (1996–2000) and Modern vs Middle Antiretroviral Therapy Eras, North American AIDS Cohort Collaboration on Research and Design, January 1996–
December 2010
Viral Hepatitis Status
Modern vs Early ART Era Modern vs Middle ART Era Middle vs Early ART Era
aIRR 95% CI aIRR 95% CI aIRR 95% CI
Overall 0.98 .72, 1.33 0.97 .77, 1.22 1.01 .76, 1.35
HBV-, HCV- 1.24 .63, 2.31 1.03 .66, 1.61 1.21 .63, 2.31
HCV+ only 0.95 .61, 1.47 1.12 .79, 1.58 0.85 .57, 1.27
HBV+ only 0.95 .40, 2.26 0.69 .38, 1.26 1.37 .62, 3.01
HBV+, HCV+ 1.52 .46, 5.02 1.88 .79, 4,45 0.81 .25, 2.60
HBV and HCV not assessed 1.29 .37, 4.49 0.71 .28, 1.82 1.81 .66, 4.93
Incidence rate ratios were estimated using a Poisson regression model stratified by hepatitis B virus (HBV) and hepatitis C virus (HCV) status and adjusted for age, sex, race, cohort and time-
varying CD4 and human immunodeficiency virus RNA.
Abbreviations: aIRR, adjusted incidence rate ratio; ART, antiretroviral therapy; CI, confidence interval.
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among coinfected patients as these treatments become used
more widely in North America.
The additional impact of long-term HBV viral control
through the dual activity of nucleos(t)ide analogs would be ex-
pected to reduce complications related to chronic HBV infec-
tion. HBV suppression has been shown to reduce liver-related
outcomes in HBV monoinfection [32, 33] and to reduce hepatic
decompensation in triply infected patients [34]. However, there
are little long-term data on the impact of HBV DNA suppres-
sion on liver disease progression in HIV coinfection.
When comparing the early to the middle ART era (when
TDF was approved), TDF uptake increased dramatically; how-
ever, no appreciable change in the rates of ESLD events were
observed among HBV-infected persons. There is some sugges-
tion that ESLD events were decreasing in the modern ART era
(40% lower than in the early ART era), although given the rel-
atively few events observed, the lower bound of the 95% CI was
consistent with no change. The HBV-infected group was in fact
the only one to show any such reduction in ESLD, suggesting
that HBV suppression associated with anti-HBV active ART in-
deed may lead to reduced event rates but that its impact may
take years to be achieved.
One reason for continued high ESLD rates among HIV/HBV
patients in the modern ART era may be that a large proportion
(35%) were not actually receiving optimal HBV suppressive
therapy with TDF. In fact, 27% of HBV-coinfected patients
were not receiving any therapy for HIV despite guideline rec-
ommendations that all HIV/HBV-infected patients be consid-
ered for HIV treatment [22]. This clearly represents a missed
opportunity for ESLD prevention. HBV therapy also may not
be fully effective in the setting of HIV. A large proportion of
HIV/HBV-coinfected patients fail to achieve HBV DNA sup-
pression despite use of TDF-based ART [35, 36]. In coinfected
patients with prior 3TC experience receiving TDF and FTC/
3TC, HBV DNA was detected in 20% of follow-up visits over
2 years [37]. In patients receiving TDF for more than 6 years,
10% had persistent, low-level HBV detected despite adequate
adherence; however, the clinical consequences of ongoing
viral replication were unclear [38].
Finally, HIV-monoinfected patients were not spared ESLD.
Comorbidities that impact liver disease are widespread in the
population, including alcohol use and fatty liver disease, in
part, due to long-term ART toxicity. This should be the focus
of future investigation, especially as the HIV-infected popula-
tion continues to age with effective ART [39].
The NA-ACCORD comprises a large number of HIV- and
viral hepatitis–coinfected individuals with wide geographic dis-
tribution in the United States and Canada and is broadly repre-
sentative of the demography of the epidemic in the United
States [15]. We used stringent validation methods for ESLD
and accounted for competing risks of death. However, several
potential limitations are worthy of consideration. Given missing
Figure 3. Prescription of hepatitis B virus (HBV)-active antiretroviral therapies (ART; dark gray bars) overlayed with the proportion prescribed tenofovir among those receiving
HBV-active therapy (light gray bars), by viral hepatitis coinfection status and ART era, North American AIDS Cohort Collaboration on Research and Design, January 1996–
December 2010. Proportion prescribed HBV-active ART represents the number of those prescribed HBV-active agents (tenofovir [TDF], lamivudine [3TC], and emtricitabine [FTC])/
the number of those prescribed ART. The proportion prescribed TDF represents the number of those prescribed TDF/the number of those prescribed HBV-active ART and is
additionally displayed as a percentage overlying the bars. Abbreviation: HCV, hepatitis C virus.
ESLD in HIV Viral Hepatitis Coinfection • CID 2016:63 (1 November) • 1165
data, we were not able to classify all patients with hepatitis.
However, ESLD rates among those without available hepatitis
serology were very similar to rates among those monoinfected
with HIV. Lack of HCV RNA and HBV DNA testing in the ma-
jority precluded confirmation of chronic infection in all who
were categorized as having viral hepatitis. Our results, therefore,
are likely to be conservative, as a proportion may have cleared
their viral hepatitis infection spontaneously or through treat-
ment. Lack of complete data on alcohol use is a potential
limitation. However, at-risk alcohol use was common in both
HIV-monoinfected and -coinfected patients (50% and 60%–
70%, respectively) and was stable over the study period and
therefore is unlikely to be a confounder. The ART exposure
measure used was relatively crude (any use recorded in the
time period) and may have overestimated the actual time on
HBV suppressive therapy. The lack of HBV DNA measures
also prevented us from determining how effective these thera-
pies were at controlling HBV infection.
In conclusion, HIV-infected patients coinfected with HBV or
HCV are at markedly increased risk for ESLD compared with
those infected with HIV alone. The continued high incidence
of ESLD despite modern ART underscores the urgent need to
specifically address HCV and HBV infections in HIV infected
adults. Improved identification, staging, monitoring, and treat-
ment of coinfected persons should be prioritized.
Supplementary Data
Supplementary materials are available at http://cid.oxfordjournals.org.
Consisting of data provided by the author to benefit the reader, the posted
materials are not copyedited and are the sole responsibility of the author, so
questions or comments should be addressed to the author.
Notes
Author contributions. M. B. K. and K. N. A. had full access to all the
data in the study and take responsibility for the integrity of the data and the
accuracy of the data analysis. Study concept and design: M. B. K., K. N. A.,
Y. J., V. L. R., G. D. K., M. K., M. H., H. N. K., E. M., M. J. S., T. R. S., J. E. T.,
S. N., J. E., M. J. G., M. G. P., A. M., E. R. C., and R. M. Acquisition of data:
M. B. K., K. N. A., M. K., V. L. R., G. D. K., M. J. S., T. R. S., J. E. T., S. N., J. E.,
M. J. G., A. J., and R. M. Analysis and interpretation of data: M. B. K.,
K. N. A., Y. J., and B. L. Drafting of the manuscript: M. B. K., K. N. A.,
and Y. J. Critical revision of the manuscript for important intellectual con-
tent: M. B. K., B. L., V. L. R., G. D. K., M. H., H. N. K., G. S., E. M., M. J. S.,
T. R. S., J. E. T., A. C., S. N., J. E., M. J. G., A. J., M. G. P., J. G., A. M., C. L. T.,
E. R. C., and R. M. Statistical analysis: K. N. A. and Y. J. Obtained funding:
R. M. Administrative, technical, or material support: M. B. K., K. N. A.,
M. K., and R. M. Study supervision: M. B. K., K. N. A., and R. M.
Financial support. This work was supported by numerous grants
(grants U01-AI069918, U01-AA013566, U01-AA020790, U01-AI31834,
U01-AI34989, U01-AI34993, U01-AI34994, U01-AI35004, U01-AI35039,
U01-AI35040, U01-AI35041, U01-AI35042, UM1-AI35043, U01-AI37613,
U01-AI37984, U01-AI38855, U01-AI38858, U01-AI42590, U01-AI68634,
U01-AI68636, U01-AI69432, U01-AI69434, U01-DA036935, U01-
HD32632, U10-EY08052, U10-EY08057, U10-EY08067, U24-AA020794,
U54-MD007587, UL1-RR024131, UL1-TR000083, F31-DA037788, G12-
MD007583, K01-AI071754, K01-AI093197, K23-EY013707, K24-DA00432,
K24-AI065298, KL2-TR000421, MO1-RR-00052, N02-CP55504, P30-
AI027763, P30-AI094189, P30-AI27757, P30-AI27767, P30-AI036219, P30-
AI50410, P30-AI54999, P30-MH62246, R01-AA16893, R01-CA165937,
U01-DA036297, K24-AI118591, R01-DA11602, R01-DA12568, R24-
AI067039, R56-AI102622, Z01-CP010214, and Z01-CP010176) from the
National Institutes of Health; contract CDC200-2006-18797 from the Centers
for Disease Control and Prevention; contract 90047713 from the Agency for
Healthcare Research and Quality; contract 90051652 from the Health Re-
sources and Services Administration; grants TGF-96118, HCP-97105, CBR-
86906, CBR-94036 from the Canadian Institutes of Health Research, Canada;
Canadian Institutes of Health Research (CIHR) New Investigator award (A.
B.); Fonds de recherche Santé-Québec/(FRQ-S)/Réseau SIDA/Maladies Infec-
tieuses; Ontario Ministry of Health and Long Term Care; and the Govern-
ment of Alberta, Canada. Additional support was provided by the
Intramural Research Program of the National Cancer Institute and the Na-
tional Institutes of Health. M. B. K. is supported by a Chercheurs nationaux
career award from the FRQ-S.
Potential conflicts of interest. M.B.K. has received research support
from Merck and Viiv Healthcare and consulting fees from ViiV Healthcare,
Abbvie, BristolMyersSquibb, Merck, and Gilead. K. N. A. reports personal
fees from Gilead Sciences outside the submitted work. V. L. R. has received
investigator-initiated research grant support (to the University of Pennsyl-
vania) from AstraZeneca and Gilead Sciences. G. S. has acted as a speaker
for Merck, Vertex, Gilead, Echosens; served as an advisory board member
for Boheringer Ingelheim and Novartis, and has received research funding
from Vertex, ViiV, and Merck M. J. S. reports grants from Pfizer and Merck
outside the submitted work. J. E. T. has served on an advisory board for Al-
lergan and has served as a consultant to Santen and XOMA. J. E. is a con-
sultant to Merck, BristolMyersSquibb, GlaxoSmithKline, and ViiV
Healthcare. M. J. G. has served on advisory boards for Abbott, ViiV, Gilead,
Janssen, and Merck. All other authors report no potential conflicts. All au-
thors have submitted the ICMJE Form for Disclosure of Potential Conflicts
of Interest. Conflicts that the editors consider relevant to the content of the
manuscript have been disclosed.
References
1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29(suppl 1):74–81.
2. Sun HY, Sheng WH, Tsai MS, Lee KY, Chang SY, Hung CC. Hepatitis B virus co-
infection in human immunodeficiency virus-infected patients: a review. World J
Gastroenterol 2014; 20:14598–614.
3. Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ. HIV-HBV coinfection—a global
challenge. N Engl J Med 2012; 366:1749–52.
4. Forrester JE, Rhee MS, McGovern BH, Sterling RK, Knox TA, Terrin N. The as-
sociation of HIV viral load with indirect markers of liver injury. J Viral Hepat
2012; 19:e202–11.
5. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus
infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect
Dis 2001; 33:562–9.
6. Anderson JP, Tchetgen Tchetgen EJ, Lo Re V III, et al. Antiretroviral therapy
reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-
coinfected veterans. Clin Infect Dis 2014; 58:719–27.
7. Lo Re V III, Kallan MJ, Tate JP, et al. Hepatic decompensation in antiretroviral-
treated patients co-infected with HIV and hepatitis C virus compared with hepa-
titis C virus-monoinfected patients: a cohort study. Ann Intern Med 2014;
160:369–79.
8. Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected
patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999;
160:659–65.
9. Klein MB, Rollet-Kurhajec KC, Moodie EE, et al. Mortality in HIV-hepatitis C co-
infected patients in Canada compared to the general Canadian population (2003–
2013). AIDS 2014; 28:1957–65.
10. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected
with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006;
166:1632–41.
11. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus
resistance to lamivudine in human immunodeficiency virus-infected patients.
Hepatology 1999; 30:1302–6.
12. Hoff J, Bani-Sadr F, Gassin M, Raffi F. Evaluation of chronic hepatitis B virus
(HBV) infection in coinfected patients receiving lamivudine as a component of
anti-human immunodeficiency virus regimens. Clin Infect Dis 2001; 32:963–9.
13. Kosi L, Reiberger T, Payer BA, et al. Five-year on-treatment efficacy of lamivudine-,
tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected
patients. J Viral Hepat 2012; 19:801–10.
1166 • CID 2016:63 (1 November) • Klein et al
14. Gange SJ, Kitahata MM, Saag MS, et al. Cohort profile: the North American AIDS
Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol
2007; 36:294–301.
15. Althoff KN, Buchacz K, Hall HI, et al. U.S. trends in antiretroviral therapy use,
HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-
infected persons, 2000 to 2008. Ann Intern Med 2012; 157:325–35.
16. Kitahata MM, Drozd DR, Crane HM, et al. Ascertainment and verification of end-
stage renal disease and end-stage liver disease in the North American AIDS cohort
collaboration on research and design. AIDS Res Treat 2015; 2015:923194.
17. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict
both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepa-
tology 2003; 38:518–26.
18. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive
index to predict significant fibrosis in patients with HIV/HCV coinfection. Hep-
atology 2006; 43:1317–25.
19. Department of Health and Human Services. Guidelines for the Use of Antiretro-
viral Agents in HIV-1-Infected Adults and Adolescents. DHHS. 2001.
20. Department of Health and Human Services. Guidelines for the Use of Antiretro-
viral Agents in HIV-1 Infected Adults and Adolescents. DHHS. 2004.
21. US Food and Drug Administration. Drug Approval Package. Available at: http://
www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-356_Viread.cfm. Accessed
18 August 2015.
22. Department of Health and Human Services. Guidelines for the Use of Antiretro-
viral Agents in HIV-1-Infected Adults and Adolescents. 2006.
23. Grambauer N, Schumacher M, Dettenkofer M, Beyersmann J. Incidence densities
in a competing events analysis. Am J Epidemiol 2010; 172:1077–84.
24. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/
HCV-coinfected patients with successful HIV suppression using antiretroviral
therapy. J Hepatol 2006; 44:47–55.
25. Grint D, Peters L, Rockstroh JK, et al. Liver-related death among HIV/hepatitis C
virus-co-infected individuals: implications for the era of directly acting antivirals.
AIDS 2015; 29:1205–15.
26. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people
with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014;
384:241–8.
27. Kovari H, Ledergerber B, Cavassini M, et al. High hepatic and extrahepatic mor-
tality and low treatment uptake in HCV-coinfected persons in the Swiss HIV co-
hort study between 2001 and 2013. J Hepatol 2015; 63:573–80.
28. van der Meer AJ, Wedemeyer H, Feld JJ, et al. Life expectancy in patients with
chronic HCV infection and cirrhosis compared with a general population.
JAMA 2014; 312:1927–8.
29. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for
hepatitis C in the United States. Hepatology 2009; 50:1750–5.
30. Grebely J, Raffa JD, Lai C, et al. Low uptake of treatment for hepatitis C virus in-
fection in a large community-based study of inner city residents. J Viral Hepat
2009; 16:352–8.
31. Del Bello D, Nagy FI, Hand J, et al. Direct-acting antiviral-based therapy for chronic
hepatitis C virus in HIV-infected patients. Curr Opin HIVAIDS 2015; 10:337–47.
32. Lampertico P, Invernizzi F, Vigano M, et al. The long-term benefits of nucleos(t)ide
analogs in compensated HBV cirrhotic patients with no or small esophageal varices:
a 12-year prospective cohort study. J Hepatol 2015; 63:1118–25.
33. KimWR, Loomba R, Berg T, et al. Impact of long-term tenofovir disoproxil fuma-
rate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
Cancer 2015; 121:3631–8.
34. Lo Re V III, Wang L, Devine S, Baser O, Olufade T. Hepatic decompensation in
patients with HIV/hepatitis B virus (HBV)/hepatitis C virus (HCV) triple infec-
tion versus HIV/HCV coinfection and the effect of anti-HBV nucleos(t)ide ther-
apy. Clin Infect Dis 2014; 59:1027–31.
35. Hafkin JS, Osborn MK, Localio AR, et al. Incidence and risk factors for incomplete
HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-
based therapy. J Viral Hepat 2014; 21:288–96.
36. Kim HN, Rodriguez CV, Van Rompaey S, et al. Factors associated with delayed
hepatitis B viral suppression on tenofovir among patients coinfected with HBV-
HIV in the CNICS cohort. J Acquir Immune Defic Syndr 2014; 66:96–101.
37. Matthews GV, Seaberg EC, Avihingsanon A, et al. Patterns and causes of subop-
timal response to tenofovir-based therapy in individuals coinfected with HIV and
hepatitis B virus. Clin Infect Dis 2013; 56:e87–94.
38. Boyd A, Gozlan J, Maylin S, et al. Persistent viremia in human immunodeficiency
virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological
and clinical implications. Hepatology 2014; 60:497–507.
39. Sebastiani G, Rollet-Kurhajec KC, Pexos C, Gilmore N, Klein MB. Incidence and
predictors of hepatic steatosis and fibrosis by serum biomarkers in a large cohort of
human immunodeficiency virus mono-infected patients. Open Forum Infect Dis
2015; 2:1–8.
APPENDIX
Additional Contributions
NA-ACCORD Collaborating Cohorts and Representatives
AIDS Link to the IntraVenous Experience: Gregory D. Kirk.
Adult AIDS Clinical Trials Group Longitudinal Linked Ran-
domized Trials: Constance A. Benson and Ronald J. Bosch. Fen-
way Health HIV Cohort: Stephen Boswell, Kenneth H. Mayer,
and Chris Grasso. HAART Observational Medical Evaluation
and Research: Robert S. Hogg, P. Richard Harrigan, Julio SG
Montaner, Angela Cescon, and Hasina Samji. HIV Outpatient
Study: John T. Brooks and Kate Buchacz. HIV Research Net-
work: Kelly A. Gebo and Richard D. Moore. Johns Hopkins
HIV Clinical Cohort: Richard D. Moore. John T. Carey Special
Immunology Unit Patient Care and Research Database, Case
Western Reserve University: Benigno Rodriguez. Kaiser Perma-
nente Mid-Atlantic States: Michael A. Horberg. Kaiser Perma-
nente Northern California: Michael J. Silverberg. Longitudinal
Study of Ocular Complications of AIDS: Jennifer E. Thorne.
Multicenter Hemophilia Cohort Study–II: James J. Goedert.
Multicenter AIDS Cohort Study: Lisa P. Jacobsonc and Gyp-
syamber D’Souza. Montreal Chest Institute Immunodeficiency
Service Cohort: Marina B. Klein. Ontario HIV Treatment Net-
work Cohort Study: Sean B. Rourke, Ann N. Burchell, and Anita
R. Rachlis. Retrovirus Research Center, Bayamon Puerto Rico:
Robert F. Hunter-Mellado and Angel M. Mayor. Southern Al-
berta Clinic Cohort: M. John Gill. Studies of the Consequences
of the Protease Inhibitor Era: Steven G. Deeks and Jeffrey
N. Martin. Study to Understand the Natural History of HIV/
AIDS in the Era of Effective Therapy: Pragna Patel and John
T. Brooks. University of Alabama at Birmingham 1917 Clinic
Cohort: Michael S. Saag, Michael J. Mugavero, and James Wil-
lig. University of North Carolina at Chapel Hill HIV Clinic Co-
hort: Joseph J. Eron and Sonia Napravnik. University of
Washington HIV Cohort: Mari M. Kitahata, Heidi M. Crane,
and H. Nina Kim. Daniel R. Drozd Vanderbilt Comprehensive
Care Clinic HIV Cohort: Timothy R. Sterling, David Haas, Sally
Bebawy, and Megan Turner. Veterans Aging Cohort Study:
Amy C. Justice, Robert Dubrow, and David Fiellin. Women’s
Interagency HIV Study: Stephen J. Gange and Kathryn Anastos.
NA-ACCORD Study Administration
Executive Committee: Richard D. Moore, Michael S. Saag,
Stephen J. Gange, Mari M. Kitahata, Keri N. Althoff, Rosemary
G. McKaig, Amy C. Justice, and Aimee M. Freeman. Adminis-
trative Core: Richard D. Moore, Aimee M. Freeman, and Carol
Lent. Data Management Core: Mari M. Kitahata, Stephen
E. Van Rompaey, Heidi M. Crane, Daniel R. Drozd, Liz Morton,
Justin McReynolds, and William B. Lober. Epidemiology and
Biostatistics Core: Stephen J. Gange, Keri N. Althoff, Alison
G. Abraham, Bryan Lau, Jinbing Zhang, Jerry Jing, Elizabeth
Golub, Shari Modur, Cherise Wong, Brenna Hogan, Weiqun
Tong, and Bin Liu.
ESLD in HIV Viral Hepatitis Coinfection • CID 2016:63 (1 November) • 1167
